Analyst: Darzalex sales figures could result in Genmab upgrade

Sales of the Genmab-developed drug Darzalex, which is in-licensed to Jonhson & Johson, have gone so well in the third quarter that one analyst thinks a guidance upgrade from Genmab could likely be on its way.

Photo: Sydbank/PR

The bone marrow cancer treatment Darzalex exceeded analysts' third quarter sales expectations with around DKK 850m.

The total market sales from the Johnson & Johnson-owned Janssen, which obtained Darzalex through an in-licensing agreement, could very well end up also exceeding the USD 5.6-5.9bn estimate that Genmab has included in its 2021 guidance.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs